JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
See More: http://goo.gl/tW6DQL
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
4.3.2 5EU 39<br />
4.3.3 Japan 42<br />
4.3.4 Canada 44<br />
4.3.5 China 45<br />
4.3.6 India 47<br />
4.4 <strong>Forecast</strong> Methodology 48<br />
4.4.1 Sources Used 50<br />
4.4.2 Sources Not Used 56<br />
4.4.3 <strong>Forecast</strong> Assumptions <strong>and</strong> Methods 57<br />
4.5 Epidemiological <strong>Forecast</strong> of UC (2012-<strong>2022</strong>) 63<br />
4.5.1 Incident Cases of UC 63<br />
4.5.2 Age-Specific Incident Cases of UC 65<br />
4.5.3 Sex-Specific Incident Cases of UC 66<br />
4.5.4 Age-St<strong>and</strong>ardized Incidence Rates 69<br />
4.6 Epidemiological <strong>Forecast</strong> for UC Prevalent Cases (2012-<strong>2022</strong>) 70<br />
4.6.1 Prevalent Cases of UC 70<br />
4.6.2 Age-Specific Prevalent Cases of UC 72<br />
4.6.3 Sex-Specific Prevalent Cases of UC 74<br />
4.6.4 Age-St<strong>and</strong>ardized Prevalence Rate of UC in All <strong>Market</strong>s 76<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language